NR1H4 and Hepatic steatosis: The activation by the FXR agonist fexaramine in mice reduces weight gain and steatosis via fibroblast growth factor 15 (FGF15) signaling [73], conversely also the intestinal FXR antagonism attenuates hepatic steatosis reducing ceramides and SREBP1 signaling [69].